The University of Melbourne

St. Vincent's Institute of Medical Research

Agen Biomedical Ltd.

Agen Limited

Genentech, Inc.

Dartmouth College

Bruce E Kemp

Thomas J Martin

Richard E Wettenhall

Peter G Bundesen

Dennis B Rylatt

Carmel J Hillyard

Jane M Moseley

R Glenn Hammonds, Jr

Geoffrey Charles Nicholson

Lee A Witters

David I Stapleton

Kenneth I Mitchelhill

Anna J Fenton

AMP activated protein kinase

Antibody reagents capable of binding epitopes of PTHrP and a kit for the detection of PTHrP or fragments thereof comprising one or more antibody reagents capable of binding to epitopes of PTHrP.

Antibody having binding specificity to parathyroid hormone related

A sub-unit or fragment of parathyroid hormone related protein having the following characteristics:

Protein active in humoral hypercalcemia of malignancy-PTHrP

Polypeptides having bone resorption inhibitory activity comprising

Detection of mammalian immunodeficiency viruses

Substantially pure parathyroid hormone related protein (PTHrP) active in humoral hypercalcemia of malignancy and sub-units and fragments thereof. Antibody reagents capable of binding to epitopes of PTHrP. Methods and kits for the detection of PTHrP.

Protein active in humoral hypercalcemia of malignancy-PthrP

In an erythrocyte agglutination assay, the agglutination reagent comprises at least one erythrocyte binding molecule coupled to at least one specific analyte binding molecule wherein the erythrocyte binding molecule does not cause agglutination when incubated with erythrocytes in the absence of analyte (in the case of a direct assay) or analyte binding reagent (in the case of an indirect assay). Preferably, the erythrocytes are endogenous to the blood sample to be tested, that is, a whole blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.

Erythrocyte agglutination assay

Protein active in humoral hypercalcemia of malignancy-PTHRP

In a novel, erythrocyte agglutination assay, the agglutination reagent comprises at least one erythrocyte binding molecule coupled to at least one specific analyte binding molecule wherein the erythrocyte binding molecule does not cause agglutination when incubated with erythrocytes in the absence of analyte (in the case of a direct assay) or analyte binding reagent (in the case of an indirect assay). Preferably, the erythrocytes are endogenous to the blood sample to be tested, that is, a whole blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.

In an erythrocyte agglutination assay, the agglutination reagent comprises at least one erythrocyte binding molecule coupled to at least one specific analyte binding molecule wherein the erythrocyte binding molecule does not cause agglutination when incubated with erythrocytes in the absence of analyte. Preferably, the erythrocytes are endogenous to the blood sample to be tested, that is, a whole blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.

Growing community of inventors

Kew, Australia

Bruce E Kemp